US pharmaceutical Pfizer and its German partner BioNTech on Monday announced positive results from trials of their COVID-19 vaccine in children age 5-11, Anadolu Agency reports. The Phase 2/3 trial showed "a favorable safety profile and robust neutralizing antibody responses," said a joint statement by the firms. The trial had a two-dose regimen of 10 micrograms administered 21 days apart, or one-third of the 30 microgram dose used for people 12 and older. "Since July, pediatric cases of COVID-19 have risen by about 240% in the US – underscoring the public health need for vaccination," Pfizer Chairman and CEO Albert Bourla said in the statement. "We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children," he added.